<DOC>
	<DOCNO>NCT01638910</DOCNO>
	<brief_summary>To evaluate efficacy safety combine oral contraceptive estradiol valerate dienogest healthy female subject .</brief_summary>
	<brief_title>Efficacy Safety Combined Oral Contraceptive Estradiol Valerate Dienogest Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Healthy woman 18 50 entire study , except woman enrol India age 18 40 year , request contraception Smokers may exceed 35 year age Pregnancy lactation ( delivery , abortion , lactation within less three cycle start treatment ) Body mass index ( BMI ) &gt; 32 kg/m2 Any disease condition may worsen hormonal treatment Undiagnosed abnormal genital bleed Other contraceptive method sterilization , hormonal contraception , IUD within 30 day Visit 1 , monthly contraceptive injection within period three time injection interval start treatment Any medication could result excessive accumulation , impaired metabolism , alter excretion study drug interfere conduct study interpretation result</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>oral contraception</keyword>
	<keyword>estradiol valerate</keyword>
	<keyword>dienogest</keyword>
</DOC>